GRN and Alzheimer disease: To be specific, incremental GSTP1 (OR = 1.62; 95% CI, 1.31–2.01; P = 1.00 × 10−5), MYZAP (OR = 2.43; 95% CI, 1.56–3.78; P = 4.13 × 10−13), BIN1 (OR = 2.26; 95% CI, 1.82–2.82; P = 4.13 × 10−13) and Siglec-3 (OR = 1.05; 95% CI, 1.03–1.08; P = 6.19 × 10−5) increased the risk of AD, whereas elevated SERPINF2 (OR = 0.61; 95% CI, 0.50–0.75; P = 3.02 × 10−6), GRN (OR = 0.66; 95% CI, 0.58–0.76; P = 7.65 × 10−7), PILRA isoform FDF03-deltaTM (OR = 0.95; 95% CI, 0.93–0.97; P = 2.03 × 10−5), PILRA isoform FDF03-M14 (OR = 0.95; 95% CI, 0.93–0.97; P = 2.03 × 10−5) decreased the risk of AD.